151 related articles for article (PubMed ID: 34613525)
21. Usefulness of optimized gadolinium-enhanced fast fluid-attenuated inversion recovery MR imaging in revealing lesions of the brain.
Melhem ER; Bert RJ; Walker RE
AJR Am J Roentgenol; 1998 Sep; 171(3):803-7. PubMed ID: 9725320
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
23. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.
Barajas RF; Phillips JJ; Parvataneni R; Molinaro A; Essock-Burns E; Bourne G; Parsa AT; Aghi MK; McDermott MW; Berger MS; Cha S; Chang SM; Nelson SJ
Neuro Oncol; 2012 Jul; 14(7):942-54. PubMed ID: 22711606
[TBL] [Abstract][Full Text] [Related]
24. Advanced magnetic resonance imaging in glioblastoma: a review.
Shukla G; Alexander GS; Bakas S; Nikam R; Talekar K; Palmer JD; Shi W
Chin Clin Oncol; 2017 Aug; 6(4):40. PubMed ID: 28841802
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid changes after intravenous injection of gadolinium chelate: assessment by FLAIR MR imaging.
Bozzao A; Floris R; Fasoli F; Fantozzi LM; Colonnese C; Simonetti G
Eur Radiol; 2003 Mar; 13(3):592-7. PubMed ID: 12594563
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of High-Field Intraoperative MRI in the Detectability of Residual Tumor in Glioma Grade IV Resections.
Heßelmann V; Mager AK; Goetz C; Detsch O; Theisgen HK; Friese M; Schwindt W; Gottschalk J; Kremer P
Rofo; 2017 Jun; 189(6):519-526. PubMed ID: 28591887
[No Abstract] [Full Text] [Related]
27. Blood-Brain Barrier Opening with MRI-guided Focused Ultrasound Elicits Meningeal Venous Permeability in Humans with Early Alzheimer Disease.
Mehta RI; Carpenter JS; Mehta RI; Haut MW; Ranjan M; Najib U; Lockman P; Wang P; D'haese PF; Rezai AR
Radiology; 2021 Mar; 298(3):654-662. PubMed ID: 33399511
[TBL] [Abstract][Full Text] [Related]
28. Standard deviations of MR signal intensities show a consistent trend during imaging follow-ups for glioblastoma patients when corrected for non-biological heterogeneity due to hardware and software variation.
Sarkar S; Rojas R; Lespinasse E; Zhang XF; Zeron R
Clin Neurol Neurosurg; 2023 Jan; 224():107553. PubMed ID: 36502651
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid enhancement on fluid attenuated inversion recovery images after carotid artery stenting with neuroprotective balloon occlusions: hemodynamic instability and blood-brain barrier disruption.
Ogami R; Nakahara T; Hamasaki O; Araki H; Kurisu K
Cardiovasc Intervent Radiol; 2011 Oct; 34(5):936-41. PubMed ID: 21127870
[TBL] [Abstract][Full Text] [Related]
30. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
[TBL] [Abstract][Full Text] [Related]
31. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
[TBL] [Abstract][Full Text] [Related]
32. Correlation of Tumor Perfusion Between Carbon-13 Imaging with Hyperpolarized Pyruvate and Dynamic Susceptibility Contrast MRI in Pre-Clinical Model of Glioblastoma.
Park I; Lupo JM; Nelson SJ
Mol Imaging Biol; 2019 Aug; 21(4):626-632. PubMed ID: 30225760
[TBL] [Abstract][Full Text] [Related]
33. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.
Vrabec M; Van Cauter S; Himmelreich U; Van Gool SW; Sunaert S; De Vleeschouwer S; Suput D; Demaerel P
Neuroradiology; 2011 Oct; 53(10):721-31. PubMed ID: 21107549
[TBL] [Abstract][Full Text] [Related]
34. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
35. FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series.
Certo F; Altieri R; Maione M; Schonauer C; Sortino G; Fiumanò G; Tirrò E; Massimino M; Broggi G; Vigneri P; Magro G; Visocchi M; Barbagallo GMV
Oper Neurosurg (Hagerstown); 2021 Jan; 20(2):151-163. PubMed ID: 33035343
[TBL] [Abstract][Full Text] [Related]
36. Relationship between contrast enhancement on fluid-attenuated inversion recovery MR sequences and signal intensity on T2-weighted MR images: visual evaluation of brain tumors.
Kubota T; Yamada K; Kizu O; Hirota T; Ito H; Ishihara K; Nishimura T
J Magn Reson Imaging; 2005 Jun; 21(6):694-700. PubMed ID: 15906343
[TBL] [Abstract][Full Text] [Related]
37. Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma.
Shen Z; Liu T; Yang Z; Zhou Z; Tang W; Fan W; Liu Y; Mu J; Li L; Bregadze VI; Mandal SK; Druzina AA; Wei Z; Qiu X; Wu A; Chen X
Biomaterials; 2020 Mar; 235():119783. PubMed ID: 31981762
[TBL] [Abstract][Full Text] [Related]
38. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
39. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
